News
MHRA (UK) approves Tukysa for the treatment of advanced HER2-positive breast cancer.- Seagen
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Tukysa (tucatinib + trastuzumab + capecitabine), from Seagen, for the treatment of advanced HER2-positive breast cancer. It has authorised the Tukysa combination for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have previously been treated with at least two prior anti-HER2 treatment regimens. Approval is based on results from the HER2CLIMB trial, that enrolled 612 patients with HER2-positive unresectable locally advanced or metastatic breast cancer who had previously received – separately or in combination – trastuzumab, pertuzumab and ado-trastuzumab emtansine (T-DM1).
Condition: Breast Cancer HER2+
Type: drug